Results 181 to 190 of about 5,781 (240)

From Mechanism to Medicine: Peptide-Based Approaches for Cancer Diagnosis and Therapy. [PDF]

Biomolecules
Gouveia MJ, Campanhã J, Barbosa F, Vale N.   +3 more
europepmc   +1 more source

Peptide Receptor Radionuclide Therapy with Lu-177-DOTATATE and Monitoring with Somatostatin Receptor PET/CT in Patients with Advanced Differentiated Thyroid Carcinoma. [PDF]

Mol Imaging Biol
Kunte SC, Wenter VU, Holzgreve A, Sheikh GT, Widjaja L, Gildehaus FJ, Lindner S, Schirrmacher R, Spitzweg C, Auernhammer CJ, Werner RA, Zacherl MJ.   +11 more
europepmc   +1 more source

Very good effect of rescue treatment with ¹⁷⁷Lu-DOTATATE in the patient with advanced metastatic atypical lung carcinoid. [PDF]

Rep Pract Oncol Radiother
Poniatowska ME, Galińska B, Kurkowska S, Malarz M, Piwowarska-Bilska H, Becht R, Birkenfeld B.   +6 more
europepmc   +1 more source

The therapeutic efficacy of ²²⁵Ac-DOTATATE in neuroendocrine tumors: a preliminary meta-analysis. [PDF]

Front Oncol
Ma J, Ji Y, Yao Z, Yangqing J, Zhang C.
europepmc   +1 more source

ASO Author Reflections: The Challenge of Peritoneal Metastases in Patients with Small Bowel Neuroendocrine Tumors. [PDF]

Ann Surg Oncol
Chang J, Borbon LC, Sherman SK, Ear PH, Bellizzi AM, Dillon JS, Howe JR.   +6 more
europepmc   +1 more source

Peptide Receptor Radionuclide Therapy (PRRT)

, 2016
There has been tremendous progress over recent years on the development of peptide receptor radionuclide therapy (PRRT) for the treatment of a variety of cancers. In this technology, peptides radiolabeled with therapeutic radionuclides are targeted to cell-surface receptors which are often overexpressed on the membrane surface of tumor cells.
F. F. Knapp, Ashutosh Dash
openalex   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Radiographic response of desmoplastic mesenteric lesions to peptide receptor radionuclide therapy (PRRT).

Journal of Clinical Oncology, 2021
362 Background: 177Lu-dotatate PRRT is indicated in well-differentiated, SSTR+ small bowel NETs. These tumors often metastasize to mesenteric lymph nodes and produce a desmoplastic reaction, consisting of tumor cells mixed with fibrotic tissue. We hypothesized that in patients treated with 177Lu-dotatate, mesenteric tumors would remain stable even as
Eleonora Pelle, Taymeyah E. Al-Toubah, Brian Morse, Ghassan El-Haddad, Jonathan R. Strosberg   +4 more
openaire   +1 more source

Peptide receptor radionuclide therapy (PRRT) for GEP-NETs

Best Practice & Research Clinical Gastroenterology, 2012
Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues plays an increasing role in the treatment of patients with inoperable or metastasised gatroenteropancreatic neuroendocrine tumours (GEP-NETs). (90)Y-DOTATOC and (177)Lu-DOTATATE are the most used radiopeptides for PRRT with comparable tumour response rates (about 15 ...
Bergsma, Hendrik, Vliet, Esther, Teunissen, Jaap, Kam, BLR, de Herder, W.W., Peeters, Robin, Krenning, Eric, Kwekkeboom, Dik   +7 more
openaire   +3 more sources

Single institution experience with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET).

Journal of Clinical Oncology, 2020
623 Background: Neuroendocrine tumors (NETs) are rare but increasing in incidence. The only curative treatment is surgery, which in many cases is not an option due to metastatic disease at diagnosis. The NETTER-1 study showed high efficacy and low toxicity of peptide receptor radionuclide therapy (PRRT) for midgut NETs.
Heying Duan, Gaia Ninatti, Bradley Girod, Valentina Ferri, Pamela L. Kunz, George A. Fisher, Farshad Moradi, Guido Alejandro Davidzon, Benjamin Lewis Franc, Andrei Iagaru, Carina Mari   +10 more
openaire   +1 more source